Allogene Therapeutics (ALLO) Income from Continuing Operations (2018 - 2026)
Allogene Therapeutics (ALLO) posted Income from Continuing Operations of 145209000.0 for Q1 2026, down 185.38% sequentially from 50882000.0 in Q4 2025, and down 96.88% YoY from 4658436096.56 in Q1 2025.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Income from Continuing Operations for 9 years, with the latest figure at 145209000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 96.88% year-over-year to 145209000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 337659000.0 (up 16.0% YoY) and the FY2025 annual result came in at 190886000.0, up 25.9% from the prior year.
- Income from Continuing Operations slipped to 145209000.0 in Q1 2026 per ALLO's latest filing, from 50882000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 50882000.0 in Q4 2025 and troughed at 224928000.0 in Q3 2022.
- A 5-year average of 100636529.41 and a median of 81522000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 3379.13% in 2022, then soared 60.27% in 2025.
- Over 5 years, Income from Continuing Operations stood at 100538000.0 in 2022, then rose by 27.55% to 72844000.0 in 2023, then increased by 21.0% to 57544000.0 in 2024, then advanced by 11.58% to 50882000.0 in 2025, then slumped by 185.38% to 145209000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 145209000.0, 50882000.0, and 65286000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | -42.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.62 Mn |
| Mar 31, 2026 | -42.82 Mn |
| Dec 31, 2025 | -39.06 Mn |
| Sep 30, 2025 | -41.32 Mn |
| Jun 30, 2025 | -50.90 Mn |
| Mar 31, 2025 | -59.83 Mn |
| Dec 31, 2024 | -57.54 Mn |
| Sep 30, 2024 | -65.17 Mn |
| Jun 30, 2024 | -66.44 Mn |
| Mar 31, 2024 | -64.07 Mn |
| Dec 31, 2023 | -75.91 Mn |
| Sep 30, 2023 | -56.79 Mn |
| Jun 30, 2023 | -76.76 Mn |
| Mar 31, 2023 | -99.97 Mn |
| Dec 31, 2022 | -93.64 Mn |
| Sep 30, 2022 | -81.51 Mn |
| Jun 30, 2022 | -76.30 Mn |
| Mar 31, 2022 | -79.87 Mn |
| Dec 31, 2021 | 732,000.00 |
| Sep 30, 2021 | -78.19 Mn |